首页> 外文期刊>Oncogene >Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2|[sol]|neu antagonist in breast cancer cells. Evidence for a role in apoptosis
【24h】

Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2|[sol]|neu antagonist in breast cancer cells. Evidence for a role in apoptosis

机译:RAR激动剂,抗雌激素和HER-2 | [sol] | neu拮抗剂在乳腺癌细胞中诱导PDCD4肿瘤抑制基因的表达。在细胞凋亡中起作用的证据

获取原文
           

摘要

The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors, which have in vitro and in vivo growth inhibitory activity against breast cancer cells. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. Additionally, RAR-agonists and synthetic retinoids such as Ferentinide have been shown to induce apoptosis in malignant breast cells but not normal breast cells. To better define the genes involved in RAR-mediated growth inhibition of breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are potentially regulated by RAR-agonists in breast cancer cells. We found that PDCD4 (programmed cell death 4), a tumor suppressor gene presently being evaluated as a target for chemoprevention, was induced about three-fold by the RAR-selective agonist Am580, in T-47D breast cancer cells. RAR pan-agonists and Am580, but not retinoid X receptors (RXR)-agonists, stimulate the expression of PDCD4 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not induce PDCD4 expression in breast cancer cell lines, which were not growth inhibited by retinoids. We also observed that antiestrogen and the HER-2eu antagonist, Herceptin (Trastuzumab), also induced PDCD4 expression in T-47D cells, suggesting that PDCD4 may play a central role in growth inhibition in breast cancer cells. Transient overexpression of PDCD4 in T-47D (ER+, RAR+) and MDA-MB-231 (ER-, RAR-) cells resulted in apoptotic death, suggesting a role for PDCD4 in mediating apoptosis in breast cancer cells. PDCD4 protein expression has previously been reported in small ductal epithelium of normal breast. To date, there has been no report of induction of PDCD4 expression by RAR-agonists, antiestrogen or HER2eu antagonist in breast cancer cells and its potential role in apoptosis in these cells.
机译:人类乳腺肿瘤细胞的生长通过涉及细胞表面生长因子受体和类固醇/甲状腺/类维生素A受体基因家族的核受体的信号传导来调节。类固醇/甲状腺激素受体基因家族的成员,视黄酸受体(RARs)是依赖配体的转录因子,对乳腺癌细胞具有体外和体内生长抑制活性。 RAR激动剂可抑制许多人类乳腺癌细胞系的增殖,尤其是那些受雌二醇(E2)或生长因子刺激生长的细胞。此外,已显示RAR激动剂和合成类维生素A(如Ferentinide)可诱导恶性乳腺细胞凋亡,但不能诱导正常乳腺细胞凋亡。为了更好地定义涉及RAR介导的乳腺癌细胞生长抑制的基因,我们使用了寡核苷酸微阵列分析来创建数据库,这些数据库可能受乳腺癌细胞中RAR激动剂的调控。我们发现,目前被评估为化学预防靶标的肿瘤抑制基因PDCD4(程序性细胞死亡4)在T-47D乳腺癌细胞中被RAR选择性激动剂Am580诱导了约三倍。 RAR泛激动剂和Am580,但不是类视黄醇X受体(RXR)激动剂,在多种类视黄醇抑制的乳腺癌细胞系中刺激PDCD4的表达。 RAR激动剂不会在未受类维生素A抑制生长的乳腺癌细胞系中诱导PDCD4表达。我们还观察到抗雌激素药和HER-2 / neu拮抗剂赫赛汀(曲妥珠单抗)也诱导了T-47D细胞中PDCD4的表达,这表明PDCD4可能在乳腺癌细胞的生长抑制中发挥重要作用。 PDCD4在T-47D(ER +,RAR +)和MDA-MB-231(ER-,RAR-)细胞中的瞬时过表达导致凋亡死亡,这表明PDCD4在介导乳腺癌细胞凋亡中发挥作用。先前已报道PDCD4蛋白表达在正常乳腺的小导管上皮中。迄今为止,还没有关于RAR激动剂,抗雌激素或HER2 / neu拮抗剂在乳腺癌细胞中诱导PDCD4表达的报道及其在这些细胞凋亡中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号